Literature DB >> 27903098

Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept.

Carolyn I Rodriguez1, Jordana Zwerling1, Eyal Kalanthroff1, Hanyang Shen1, Maria Filippou1, Booil Jo1, Helen Blair Simpson1, Ronald M Burch1, Joseph R Moskal1.   

Abstract

Entities:  

Keywords:  AMPA; Clinical Drug Studies; GLYX-13; Ketamine; NMDA; OCD; Obsessive-Compulsive Disorder; Rapastinel

Mesh：

Substances：

Year:  2016        PMID： 27903098      PMCID： PMC5304999          DOI： 10.1176/appi.ajp.2016.16080868

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  16 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  An inventory for measuring clinical anxiety: psychometric properties.

Authors:  A T Beck; N Epstein; G Brown; R A Steer
Journal:  J Consult Clin Psychol       Date:  1988-12

3.  A rating scale for mania: reliability, validity and sensitivity.

Authors:  R C Young; J T Biggs; V E Ziegler; D A Meyer
Journal:  Br J Psychiatry       Date:  1978-11       Impact factor: 9.319

Review 4.  GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists.

Authors:  Joseph R Moskal; Ronald Burch; Jeffrey S Burgdorf; Roger A Kroes; Patric K Stanton; John F Disterhoft; J David Leander
Journal:  Expert Opin Investig Drugs       Date:  2013-11-20       Impact factor: 6.206

5.  Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale.

Authors:  David F Tolin; Jonathan S Abramowitz; Gretchen J Diefenbach
Journal:  J Clin Psychiatry       Date:  2005-12       Impact factor: 4.384

6.  Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder.

Authors:  Mark J Niciu; Beth D G Grunschel; Philip R Corlett; Christopher Pittenger; Michael H Bloch
Journal:  J Psychopharmacol       Date:  2013-05-15       Impact factor: 4.153

7.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

8.  GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

Authors:  Jeffrey Burgdorf; Xiao-lei Zhang; Katherine L Nicholson; Robert L Balster; J David Leander; Patric K Stanton; Amanda L Gross; Roger A Kroes; Joseph R Moskal
Journal:  Neuropsychopharmacology       Date:  2012-12-05       Impact factor: 7.853

9.  Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.

Authors:  Carolyn I Rodriguez; Michael Wheaton; Jordana Zwerling; Shari A Steinman; Danae Sonnenfeld; Hanga Galfalvy; Helen Blair Simpson
Journal:  J Clin Psychiatry       Date:  2016-03       Impact factor: 4.384

10.  Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Authors:  Carolyn I Rodriguez; Lawrence S Kegeles; Amanda Levinson; Tianshu Feng; Sue M Marcus; Donna Vermes; Pamela Flood; Helen B Simpson
Journal:  Neuropsychopharmacology       Date:  2013-06-19       Impact factor: 7.853
View more
  9 in total

1.  Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression.

Authors:  Claudia Delgado-Acevedo; Sebastián F Estay; Anna K Radke; Ayesha Sengupta; Angélica P Escobar; Francisca Henríquez-Belmar; Cristopher A Reyes; Valentina Haro-Acuña; Elías Utreras; Ramón Sotomayor-Zárate; Andrew Cho; Jens R Wendland; Ashok B Kulkarni; Andrew Holmes; Dennis L Murphy; Andrés E Chávez; Pablo R Moya
Journal:  Neuropsychopharmacology       Date:  2018-12-26       Impact factor: 7.853

2.  Pregenual Anterior Cingulate Dysfunction Associated with Depression in OCD: An Integrated Multimodal fMRI/1H MRS Study.

Authors:  Reza Tadayonnejad; Rangaprakash Deshpande; Olusola Ajilore; Teena Moody; Francesca Morfini; Ronald Ly; Joseph O'Neill; Jamie D Feusner
Journal:  Neuropsychopharmacology       Date:  2017-10-20       Impact factor: 7.853

Review 3.  Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13).

Authors:  Andrei-Nicolae Vasilescu; Nina Schweinfurth; Stefan Borgwardt; Peter Gass; Undine E Lang; Dragos Inta; Sarah Eckart
Journal:  Neuropsychiatr Dis Treat       Date:  2017-03-31       Impact factor: 2.570

4.  NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory.

Authors:  M Amin Khan; David R Houck; Amanda L Gross; Xiao-Lei Zhang; Cassia Cearley; Torsten M Madsen; Roger A Kroes; Patric K Stanton; Jeffrey Burgdorf; Joseph R Moskal
Journal:  Int J Neuropsychopharmacol       Date:  2018-03-01       Impact factor: 5.176

5.  Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects.

Authors:  John E Donello; Pradeep Banerjee; Yong-Xin Li; Yuan-Xing Guo; Takashi Yoshitake; Xiao-Lei Zhang; Omid Miry; Jan Kehr; Patric K Stanton; Amanda L Gross; Jeffery S Burgdorf; Roger A Kroes; Joseph R Moskal
Journal:  Int J Neuropsychopharmacol       Date:  2019-03-01       Impact factor: 5.176

Review 6.  Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines.

Authors:  Mervin Chávez-Castillo; Victoria Núñez; Manuel Nava; Ángel Ortega; Milagros Rojas; Valmore Bermúdez; Joselyn Rojas-Quintero
Journal:  Adv Pharmacol Sci       Date:  2019-01-03

Review 7.  The Neuronal Glutamate Transporter EAAT3 in Obsessive-Compulsive Disorder.

Authors:  Angélica P Escobar; Jens R Wendland; Andrés E Chávez; Pablo R Moya
Journal:  Front Pharmacol       Date:  2019-11-15       Impact factor: 5.810

8.  GLYX-13 Ameliorates Schizophrenia-Like Phenotype Induced by MK-801 in Mice: Role of Hippocampal NR2B and DISC1.

Authors:  Dongsheng Zhou; Dan Lv; Zhen Wang; Yanhua Zhang; Zhongming Chen; Chuang Wang
Journal:  Front Mol Neurosci       Date:  2018-04-11       Impact factor: 5.639

9.  Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in oxytocin efficacy for autism social core symptoms.

Authors:  Yasuhiko Kato; Hitoshi Kuwabara; Takashi Okada; Toshio Munesue; Seico Benner; Miho Kuroda; Masaki Kojima; Walid Yassin; Yosuke Eriguchi; Yosuke Kameno; Chihiro Murayama; Tomoko Nishimura; Kenji Tsuchiya; Kiyoto Kasai; Norio Ozaki; Hirotaka Kosaka; Hidenori Yamasue
Journal:  Mol Autism       Date:  2021-02-23       Impact factor: 7.509
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.